CD8A and neoplasm: To investigate the contribution of CD103 + DCs toward the effects of combination therapy, we compared MC38 tumor growth upon TIGIT blockade plus RT in WT or BATF3−/− mice, which lack CD103 + CD8 + DCs [35].